Aktieanalys

SenzaGen H2 2022: Initial take on H2 2022 results - Redeye

Redeye Publicerad: 16 Feb 2023 10:46

Redeye provides an initial take on SenzaGen’s H2 2022 report. We argue the year has been strong with total sales of SEK41.8m (SEK15.4m), which can be compared to our sales estimate of SEK46.6m. Even if the total sales were a bit lower than our full-year estimate, EBIT came in at SEK-25.1m (SEK-31.5m), which was better than our EBIT estimate of SEK-28.4m. We will provide an update shortly; however, we do not expect to make any major changes in our forecasts for the following years.

Länk till analysen i sin helhet: https://www.redeye.se/research/878570/senzagen-h2-2022-initial-take-on-h2-2022-results?utm_source=finwire&utm_medium=RSS

Nyheter om SenzaGen

Läses av andra just nu

Innehåller annonslänkar. Investeringar innebär risk (se här)

Tips: 50% rabatt hos fondroboten Opti

Dags att komma igång med sparande? Fondroboten Opti erbjuder en populär spartjänst som är perfekt för regelbundet månadssparande. Just nu får nya kunder som använder Börskollens unika kampanjkod BORSKOLLEN50 automatiskt 50 % rabatt på Optis avgift i 3 månader!